1.3 Sarcopenia & Functional Assessment

Sarcopenia & Functional Assessment in Older Adults

Sarcopenia is a progressive and generalized skeletal muscle disorder characterized by accelerated loss of muscle mass, strength, and physical function. Formally classified under the International Classification of Diseases (US ICD-10-CM code M62.84), sarcopenia is associated with increased risks of falls, fractures, physical disability, loss of independence, institutionalization, and mortality. In gerontological nutrition practice, early screening and staging of sarcopenia are vital to preserve functional autonomy through targeted medical nutrition therapy and exercise prescription.

Sarcopenia: Definition, Epidemiology & Biological Drivers

Primary sarcopenia is age-related, developing in the absence of other overt pathology. Secondary sarcopenia is provoked by inflammatory chronic disease (cancer, end-stage heart failure, chronic kidney disease), prolonged physical inactivity (bed rest, sedentary lifestyle, neurological impairment), or inadequate energy and protein intake (malabsorption, anorexia of aging, starvation).

The underlying pathophysiology of sarcopenia involves:

1. Alpha Motor Neuron Denervation: Progressive loss of spinal cord motor units with selective denervation and atrophy of fast-twitch Type II muscle fibers, which generate rapid force and power.
2. Chronic Systemic Inflammation ("Inflammaging"): Low-grade elevation of interleukin-6 (IL-6), tumor necrosis factor-alpha (TNF-alpha), and C-reactive protein (CRP), accelerating muscle proteolysis via the ubiquitin-proteasome pathway.
3. Anabolic Resistance: Blunted muscle protein synthesis response to circulating amino acids and insulin, motivating proposed higher protein amounts per meal ($0.4\text{ to } 0.5\text{ g/kg/meal}$ or $30\text{ to } 40\text{ g}$ high-leucine protein) to stimulate the mTOR pathway in older adults.
4. Endocrine Declines: Decreased growth hormone, insulin-like growth factor-1 (IGF-1), testosterone, and estrogen levels, alongside widespread vitamin D insufficiency.
5. Myosteatosis: Pathological fat accumulation in intermuscular and intramyocellular compartments, degrading muscle fiber contractility and metabolic function.

The EWGSOP2 Consensus Algorithm

The European Working Group on Sarcopenia in Older People updated consensus guidelines (EWGSOP2) established a four-step clinical algorithm: Find, Assess, Confirm, and Severity (F-A-C-S).

Step 1: Find / Screen (The SARC-F Questionnaire)

Case-finding begins with the SARC-F questionnaire, a 5-item patient-reported instrument:

• S (Strength): Difficulty lifting and carrying 10 lbs? (None = 0, Some = 1, A lot or unable = 2).
• A (Assistance in walking): Difficulty walking across a room? (None = 0, Some = 1, A lot, use aids, or unable = 2).
• R (Rise from chair): Difficulty transferring from chair or bed? (None = 0, Some = 1, A lot or unable without help = 2).
• C (Climb stairs): Difficulty climbing a flight of 10 stairs? (None = 0, Some = 1, A lot or unable = 2).
• F (Falls): Number of falls in past year? (None = 0, 1 to 3 falls = 1, 4 or more falls = 2).

Cutoff: A total score of $\ge 4\text{ points}$ (out of 10) indicates risk of sarcopenia. SARC-F has relatively high specificity but limited sensitivity; clinical suspicion can justify objective assessment despite a negative screen.

Step 2: Assess Muscle Strength (Defining Probable Sarcopenia)

EWGSOP2 established that low muscle strength is the foremost clinical indicator of sarcopenia, surpassing muscle mass as the primary predictor of poor outcomes. Documenting low muscle strength defines "probable sarcopenia":

• Isometric Handgrip Strength: Measured with a calibrated Jamar hydraulic hand dynamometer while seated with elbow flexed at 90 degrees. Three maximum contractions per hand are performed; the highest value is recorded.
  • Men: $< 27.0\text{ kg}$
  • Women: $< 16.0\text{ kg}$
• Chair Stand Test (5-Times Sit-to-Stand): Assesses lower-extremity power. The patient rises five consecutive times from an armless chair as quickly as possible with arms folded across the chest.
  • Threshold: $> 15.0\text{ seconds}$ for 5 rises (or unable to complete).

Clinical Action: Establishing probable sarcopenia justifies initiating clinical interventions—including progressive resistance exercise and targeted protein supplementation—without waiting for body composition scans.

Step 3: Confirm Muscle Quantity and Quality (DXA, BIA, and CT)

Diagnostic confirmation requires objective documentation of depleted muscle mass:

• Dual-Energy X-Ray Absorptiometry (DXA): Quantifies Appendicular Lean Mass (ALM), the sum of non-fat, non-bone lean mass in upper and lower limbs:
  • Absolute ALM: Men $< 20.0\text{ kg}$; Women $< 15.0\text{ kg}$
  • Relative ALM Adjusted for Stature ($\text{ALM}/\text{height}^2$): Men $< 7.0\text{ kg/m}^2$; Women $< 5.5\text{ kg/m}^2$
• Bioelectrical Impedance Analysis (BIA): Estimate muscle quantity with device- and population-appropriate equations. Hydration affects results; whole-body and appendicular muscle indices are not interchangeable.
• CT or MRI: Assess muscle quantity or quality in specialty practice and research. Oncology-derived L3 cutoffs are not universal EWGSOP2 thresholds.

Step 4: Grade Severity via Physical Performance

In a person with confirmed sarcopenia (low strength plus low muscle quantity/quality), compromised physical performance establishes "severe sarcopenia":

• Usual Gait Speed: Measured over a 4-meter straight track: cutoff is $\le 0.8\text{ m/s}$.
• Short Physical Performance Battery (SPPB): Evaluates balance, gait speed, and chair stands (score 0 to 12): cutoff is $\le 8\text{ points}$.
• Timed Up and Go (TUG): Measures time to stand from an armchair, walk 3 meters, turn, return, and sit down: cutoff is $\ge 20.0\text{ seconds}$.

Summary of EWGSOP2 Diagnostic Cutoff Values

Sarcopenic Obesity: Clinical Manifestations and Dilemmas

Sarcopenic obesity is the coexistence of excess adiposity with depleted skeletal muscle mass and strength. Inactive lifestyles, hypercaloric diets, and low-grade inflammation cause adipose expansion, macrophage infiltration, and fat accumulation within muscle fibers (myosteatosis).

Sarcopenic obesity represents a critical diagnostic dilemma:

• Elevated body weight and high BMI ($> 30.0\text{ kg/m}^2$) can conceal underlying muscle depletion.
• Sarcopenic obesity carries higher morbidity, cardiovascular mortality, and disability rates than obesity or sarcopenia alone.
• Energy restriction can worsen muscle loss if nutrition and exercise are inadequate. When weight reduction is appropriate, individualize energy/protein targets and the weight basis, and coordinate safe resistance exercise with the clinical team.

Illustrative Clinical Case

The following is a constructed teaching example; its course and outcomes are not a prediction for every patient.

A 76-year-old female presents after two falls at home over 6 months. Her SARC-F score is 5 points. Clinical evaluation reveals:

• Handgrip strength: 14.0 kg.
• Chair stand test: Unable to rise without arm support.
• DXA body composition: $\text{ALM} = 13.1\text{ kg}$; height is 1.58 m; $\text{ALM}/\text{height}^2 = 13.1 / (1.58)^2 = 5.25\text{ kg/m}^2$.
• 4-meter gait speed: 0.68 m/s.

Diagnostic Staging:

1. SARC-F $\ge 4$: Positive case-finding.
2. Grip strength $< 16.0\text{ kg}$: Probable sarcopenia.
3. DXA $\text{ALM}/\text{height}^2 < 5.5\text{ kg/m}^2$: Confirmed sarcopenia.
4. Gait speed $\le 0.8\text{ m/s}$: Severe sarcopenia.

Care Plan: Coordinate supervised resistance exercise and an individualized protein/energy plan. A case target of 1.2–1.5 g protein/kg/day may be appropriate after reviewing kidney function, illness, and intake. Distribute accepted protein-rich foods across meals; proposed meal/leucine amounts are not universal requirements. Evaluate vitamin D intake and deficiency for the clinical indication.

CSG Board Exam Tips & Common Traps

• Strength Trumps Mass: Under EWGSOP2, low muscle strength defines "probable sarcopenia" and serves as the clinical trigger for intervention.
• Memorize Grip Strength Cutoffs: EWGSOP2 strength thresholds are $< 27\text{ kg}$ for men and $< 16\text{ kg}$ for women.
• DXA Cutoffs: Relative ALM: $< 7.0\text{ kg/m}^2$ for men and $< 5.5\text{ kg/m}^2$ for women. Absolute ALM: $< 20\text{ kg}$ for men and $< 15\text{ kg}$ for women.
• Severe Sarcopenia Metric: Sarcopenia is graded as severe only when physical performance is impaired (gait speed $\le 0.8\text{ m/s}$, $\text{SPPB} \le 8$, or $\text{TUG} \ge 20\text{ s}$).

Primary source check

EWGSOP2 consensus, checked October 13, 2026.